Last reviewed 2026-06-02 · How we verify

Carfimat (CARFIMATE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Carfimat (generic name: CARFIMATE) is a drug. It is currently in Phase 2 development.

Carfimat is a small molecule that works by binding to a specific target in the body to produce its therapeutic effect.

Carfimat is a small molecule. It is also known by the synonyms Carfimate and Carfimato.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CARFIMATE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of Carfimat like a key that fits into a lock in the body. When it binds to its target, it helps to either block or activate a specific process that leads to the desired therapeutic effect. This can help to treat a variety of conditions, depending on the target and the specific disease being treated.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Carfimat CI brief — competitive landscape report
Carfimat updates RSS · CI watch RSS

Frequently asked questions about Carfimat

What is Carfimat?

Carfimat (CARFIMATE) is a Small molecule drug.

How does Carfimat work?

Carfimat is a small molecule that works by binding to a specific target in the body to produce its therapeutic effect.

What is the generic name of Carfimat?

CARFIMATE is the generic (nonproprietary) name of Carfimat.

What development phase is Carfimat in?

Carfimat is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing